The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma.
Grant A. McArthur
Consultant or Advisory Role - Pfizer (U)
Research Funding - Pfizer
Richard J. Young
No relevant relationships to disclose
Karen E Sheppard
Research Funding - Pfizer
Victoria Mar
No relevant relationships to disclose
Kelly Waldeck
No relevant relationships to disclose
Stephen B. Fox
Consultant or Advisory Role - Pfizer (U)
Research Funding - Pfizer
Fergal C Kelleher
No relevant relationships to disclose
Wendy Liu
No relevant relationships to disclose
Alexander Dobrovic
Research Funding - Pfizer
Richard Pearson
Research Funding - Pfizer
John Kelly
No relevant relationships to disclose
James G. Christensen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Sophia Randolph
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer